Dossier assessment
Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with advanced clear cell renal cell carcinoma that has progressed following 2 or more lines of therapy that included a PD‑(L)1 inhibitor and at least 2 vascular endothelial growth factor‑targeted therapies
- Patients < 65 years of age for whom everolimus is a suitable individualized treatment: hint of a minor added benefit
- Patients ≥ 65 years of age for whom everolimus is a suitable individualized treatment: hint of a considerable added benefit
- Patients for whom everolimus is not a suitable individualized treatment: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-09-18 A G-BA decision was published.
Project details
- Project no.
- A25-45
- Commission
- Commission awarded on 28.03.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-45_en
Connected Projects
-
Dossier assessment
Belzutifan (Von-Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Belzutifan (renal cell carcinoma) – Addendum to Project A25-45
Status: Commission completed